NewLimit Raises $130M Series B for Anti-Aging Drug Development

NewLimit, the biotechnology startup co-founded by Coinbase CEO Brian Armstrong, has secured $130 million in Series B funding led by Kleiner Perkins12. The company is developing medicines that target aging through an epigenetic approach, with the goal of increasing how long people can live healthy lives by genetically programming their cells2.

The funding round included both returning investors like Dimension Capital, Elad Gil, Garry Tan, and Patrick Collison, as well as new contributors such as Friedman, Gross, and Khos Ventures2. This latest investment follows a $40 million Series A round completed two years ago2.

Founded over four years ago by Armstrong along with GV partner Blake Bryers and stem cell expert Jacob Kimmel, NewLimit has made significant progress in developing therapies designed to rejuvenate aged cells2. The company has identified three prototype medications capable of reprogramming liver cells, with laboratory tests suggesting these treatments can restore the cells' ability to effectively metabolize fat and alcohol2.

NewLimit's evaluation method involves comparing responses of cells from younger individuals against those from older adults. According to Bryers, liver cells that undergo NewLimit's epigenetic reprogramming show behavior more similar to younger cells2. Despite these promising early results, the company still expects it will be several more years before human trials can begin2.

Sources:

1. https://firstwordpharma.com/story/5957146

2. https://techcrunch.com/2025/05/06/newlimit-founded-by-coinbase-ceo-brian-armstorng-raises-130m-to-develop-age-reversing-therapies/